Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
C Fougeroux, L Goksøyr, M Idorn, V Soroka… - Nature …, 2021 - nature.com
The rapid development of a SARS-CoV-2 vaccine is a global priority. Here, we develop two
capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of …
capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of …
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody …
There is need for effective and affordable vaccines against SARS-CoV-2 to tackle the
ongoing pandemic. In this study, we describe a protein nanoparticle vaccine against SARS …
ongoing pandemic. In this study, we describe a protein nanoparticle vaccine against SARS …
SARS‐CoV‐2 RBD neutralizing antibody induction is enhanced by particulate vaccination
The receptor‐binding domain (RBD) of the SARS‐CoV‐2 spike protein is a candidate
vaccine antigen that binds angiotensin‐converting enzyme 2 (ACE2), leading to virus entry …
vaccine antigen that binds angiotensin‐converting enzyme 2 (ACE2), leading to virus entry …
SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain
Tools to monitor SARS-CoV-2 transmission and immune responses are needed. We present
a neutralization ELISA to determine the levels of Ab-mediated virus neutralization and a …
a neutralization ELISA to determine the levels of Ab-mediated virus neutralization and a …
A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …
[PDF][PDF] Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
A safe, effective, and scalable vaccine is needed to halt the ongoing SARS-CoV-2
pandemic. We describe the structure-based design of self-assembling protein nanoparticle …
pandemic. We describe the structure-based design of self-assembling protein nanoparticle …
[PDF][PDF] SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses
The outbreak and spread of SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-
2) is a current global health emergency, and effective prophylactic vaccines are needed …
2) is a current global health emergency, and effective prophylactic vaccines are needed …
Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection
Background Vaccines that incorporate multiple SARS‐CoV‐2 antigens can further broaden
the breadth of virus‐specific cellular and humoral immunity. This study describes the …
the breadth of virus‐specific cellular and humoral immunity. This study describes the …
SARS-CoV-2 spike protein stabilized in the closed state induces potent neutralizing responses
The majority of SARS-CoV-2 vaccines in use or advanced development are based on the
viral spike protein (S) as their immunogen. S is present on virions as prefusion trimers in …
viral spike protein (S) as their immunogen. S is present on virions as prefusion trimers in …
Molecular aspects concerning the use of the SARS-CoV-2 receptor binding domain as a target for preventive vaccines
Y Valdes-Balbin, D Santana-Mederos… - ACS central …, 2021 - ACS Publications
The development of recombinant COVID-19 vaccines has resulted from scientific progress
made at an unprecedented speed during 2020. The recombinant spike glycoprotein …
made at an unprecedented speed during 2020. The recombinant spike glycoprotein …